Daptomycin treatment in Gram-positive vascular graft infections

Revillas, Francisco Arnáiz de las; Fernández-Sampedro, Marta; Arnáiz-García, Ana María; Gutiérrez‐Cuadra, Manuel; Armiñanzas, Carlos; Pulitani, Ivana; Pontón, Alejandro; Tascón, V.; García, I.; Fariñas, María Carmen

doi:10.1016/j.ijid.2018.01.009

Cited by 11 publications

(5 citation statements)

References 33 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Daptomycin may thus be of interest, since it has been shown to prevent and eradicate biofilm in a subcutaneous rat pouch model of staphylococcal infection [ 34 ]. Moreover, high doses of daptomycin have been demonstrated to be safe [ 35 ], and daptomycin is associated with favorable outcomes in the treatment of VGI [ 36 ]. Considering that polymicrobial and multidrug-resistant gram-negative bacilli are often found in VGI, as previously reported [ 26 ], anti-staphylococcal treatment has to be associated with a broad-spectrum antibiotic active against gram-negative bacilli (eg, piperacillin-tazobactam or cefepime).…”

Section: Discussionmentioning

confidence: 99%

Long-term Prognosis Following Vascular Graft Infection: A 10-Year Cohort Study

Sixt¹,

Aho²,

Chavanet

et al. 2022

Open Forum Infectious Diseases

View full text Add to dashboard Cite

Background Vascular graft infection remains a severe disease with high mortality and relapse rates. We performed a retrospective single center cohort study to highlight factors associated with long-term all-cause mortality in patients with vascular graft infection. Methods All patients hospitalized in our facility over 10 years for a vascular graft infection (VGI) were included. VGI was defined by the presence of a vascular graft or an aortic stent graft (stent or fabric), associated with two criteria among clinical, biological, imaging, or microbiological elements in favor of VGI. The primary outcome was all-cause mortality. Empirical antibiotic therapy was considered as appropriate when all involved pathogens were susceptible in vitro to the antibiotics used. The surgical strategy was defined as non-optimal when the graft was not removed in a late-onset surgery (>3 months) or no surgery was performed. Results One hundred and forty-six patients were included. Empirical antibiotic therapy was administered in 98 (67%) patients and considered appropriate in 55 (56%) patients. Surgery was performed in 136 patients (96%) and considered as optimal in 106 (73%) patients. In multivariable analysis, appropriate empirical antibiotic therapy was associated with a lower probability of mortality (Hazard Ratio=0.47; 95% Confidence Interval: 0.30-0.79; p=.002). Long term survival did not differ according to whether the surgical strategy was considered optimal or not (log rank=.66). Conclusion Appropriate empirical antibiotic therapy is a cornerstone of the management of vascular graft infection. Whenever possible, antibiotics must be associated with optimal surgical management. However, surgery could potentially be avoided in comorbid patients who are treated with appropriate antibiotics.

show abstract

Section: Discussionmentioning

confidence: 99%

Long-term Prognosis Following Vascular Graft Infection: A 10-Year Cohort Study

Sixt¹,

Aho²,

Chavanet

et al. 2022

Open Forum Infectious Diseases

View full text Add to dashboard Cite

show abstract

“…In our center, daptomycin is the first-line therapy for methicillin-resistant S. aureus bacteremia ( 6 ). Rifampin is bactericidal against S. aureus , achieves high intracellular levels, is one of the few antimicrobial agents that can penetrate biofilms, and it has been commonly used adjunctively to treat S. aureus infections ( 7 ). Thus, we first used parenteral antibiotic therapy with daptomycin; thereafter, we used prolonged oral antibiotic combination of linezolid plus rifampin ( 6 ).…”

Section: Discussionmentioning

confidence: 99%

Successful Conservative Treatment of a Large Infected Saphenous Graft Aneurysm

et al. 2020

View full text Add to dashboard Cite

We report a case of a 75-year-old man with a medical history of coronary artery bypass graft surgery and a recent graft angioplasty, who presented to our emergency department with fever. An 18F-fluorodeoxyglucose positron emission tomography demonstrated a saphenous graft infected aneurysm, which was successfully treated conservatively with antibiotic therapy. ( Level of Difficulty: Beginner. )

show abstract

“…Daptomycin (DAP) is a cyclic lipopeptide antibiotic that targets the cell membrane, where it causes rapid depolarization leading to cell death ( Montero et al, 2008 ; Pogliano et al, 2012 ; Tran et al, 2015 ; Taylor and Palmer, 2016 ). Daptomycin is an important therapeutic option for treating multi-drug-resistant infections ( Streit et al, 2004 ; Steenbergen et al, 2005 ; Fowler Jr et al, 2006 ; Yim et al, 2017 ; de Las Revillas et al, 2018 ), including vancomycin-resistant enterococci (VRE). However, daptomycin resistance in enterococcus has been increasingly reported in the last decade in both the laboratory and the clinic ( Kelesidis et al, 2011 ; Kamboj et al, 2011 ; Kelesidis et al, 2012 ; Humphries et al, 2013 ; Miller et al, 2016 ; Kinnear et al, 2019, 2020 ).…”

Section: Introductionmentioning

confidence: 99%

“…Daptomycin is an important therapeutic option for treating multi-drug-resistant infections (Streit et al, 2004;Steenbergen et al, 2005;Fowler Jr et al, 2006;Yim et al, 2017;de Las Revillas et al, 2018), including vancomycin-resistant enterococci (VRE). However, daptomycin resistance in enterococcus has been increasingly reported in the last decade in both the laboratory and the clinic (Kelesidis et al, 2011;Kamboj et al, 2011;Kelesidis et al, 2012;Humphries et al, 2013;Miller et al, 2016;Kinnear et al, 2019Kinnear et al, , 2020.…”

Section: Introductionmentioning

confidence: 99%

Heterogeneous collateral effects in daptomycin-resistantE. faecalis

Huynh,

Maltas,

Wood

2023

Preprint

View full text Add to dashboard Cite

Daptomycin, a cyclic lipopeptide antibiotic that targets the cell membrane, is an important therapeutic option for treating multi-drug-resistant infections, including vancomycin-resistant enterococci (VRE). Recent work has uncovered an array of daptomycin resistance mechanisms in enterococci, but relatively little is known about how these molecular defenses contribute to collateral effects–that is, to increased resistance or sensitivity to other drugs. In this work, we investigate collateral effects that arise during daptomycin adaptation ofE. faecalisin four independent laboratory-evolved populations. Using a combination of growth assays and both single isolate and population sequencing, we identified DAP-resistant lineages with mutations in one or more genes previously associated with DAP resistance, and these isolates are characterized by divergent phenotypic properties–including different levels of DAP resistance and different growth rates (i.e. fitness costs) in drug-free media. Interestingly, we also observed strongly divergent collateral responses to different antibiotics, particularly CRO, with collateral resistance arising in mutants harboring DAP-resistance mutations in cardiolipin synthetase (cls) or in genes linked to the two-component signaling system YxdJK (bceRor a regulated transporterycvR). By contrast, mutations inliaX, a component of a LiaFSR two-component signaling system, arose in two of the four populations, with point mutations associated with CRO-sensitivity and a large structural integration of plasmid pTEF3 associated with extreme CRO-sensitivity and a dramatically reduced growth rate. Our results reveal considerable phenotypic differences in mutations targeting the LiaSFR system and highlight trade-offs between resistance to daptomycin, collateral profiles (most notably to CRO), and drug-free growth rates in evolving lineages. As a whole, these results underscore how rich–and remarkably diverse–evolutionary dynamics can emerge even in parallel populations adapting to simple daptomycin escalation protocols.

show abstract

Daptomycin treatment in Gram-positive vascular graft infections

Abstract: The use of daptomycin and surgery for Gram-positive VGI was effective and well tolerated, and this may be a good alternative for the treatment of VGI in patients with peripheral arterial disease in whom renal insufficiency is common.

Cited by 11 publications

References 33 publications

Long-term Prognosis Following Vascular Graft Infection: A 10-Year Cohort Study

Long-term Prognosis Following Vascular Graft Infection: A 10-Year Cohort Study

Successful Conservative Treatment of a Large Infected Saphenous Graft Aneurysm

Heterogeneous collateral effects in daptomycin-resistantE. faecalis

Contact Info

Product

Resources

About